NCT02318121

Brief Summary

Prolonged labour is a cause of maternal mortality and morbidity and perinatal mortality and morbidity. Prolonged labour is most often defined as onset of regular , rhythmical painful contractions accompanied by cervical dilatation where labour is longer than 24 hours.prolonged active phase should not last longer than 12 hours without full assessment in a facility able to offer management and treatment of complications.Causes of prolonged labour usually due to poor or uncoordinated uterine action , fetal head malposition , and or abnormal pelvis either due to bone or soft tissue obstruction. Arrested or prolonged labor is a frequent indication of cesarean delivery.Prolonged labor is also associated with increased pain and negative birth experience. Women with a prolonged first stage of labor have experienced a higher rate of postpartum hemorrhage, chorioamnionitis and neonatal admission to the intensive care unit. Caesarean section rates are over 20% in many developed countries and have increased nearly four-fold relative to the 5% rate observed in the early 1970s. The main diagnosis contributing to this increase is dystocia or prolonged labor.Data obtained from local hospital records showed that Caesarean section rate in Assiut University Women's Health Hospital is 47.96% at 2013. Dystocia is a term used for delay of labor progress and usually refers to abnormally slow cervical dilatation.It has been proposed that the partogram should include, as a diagnostic criterion, a 1 cm/hour line originating at admission. The World Health Organization has proposed a modified partogram that recommends that active phase be diagnosed only at 4 cm or more. Oxytocin augmentation of uterine contractions with or without amniotomy is widely used in the modern obstetric practice to treat a slow labour, although the timing of oxytocin initiation and amniotomy may vary widely.This intervention is based on the hypothesis that the most frequent cause of dystocia is inadequate uterine contraction. The mechanism by which amniotomy speeds up labour remains unclear it is thought that when the membranes are ruptured ,the production and release of prostaglandins and oxytocin increases resulting in stronger contractions and quicker cervical dilatation. I has been found that early intervention (augmentation versus routine care ) with amniotomy and oxytocin to be associated with a modest reduction in the risk of caesarean section. Moreover, amniotomy found to be associated with an increased risk of cesarean delivery compared with women without amniotomy for shortening of spontaneous labour. The 3 methods ( Amniotomy, Oxytocin or both) used for augmentation of labor in different settings without a real conclusion which is better.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Apr 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 5, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 17, 2014

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

November 21, 2017

Status Verified

November 1, 2017

Enrollment Period

5 months

First QC Date

October 5, 2014

Last Update Submit

November 20, 2017

Conditions

Keywords

Labor, prolonged labor, augmentation of labor

Outcome Measures

Primary Outcomes (1)

  • Rate of cervical dilatation

    The rate of cervical dilation cm/ hour

    every hour up to full cervical dilatation

Secondary Outcomes (2)

  • Augmentation delivery time

    Time ( in minutes) between the start of augmentation of labor up to the delivery of the head

  • Apgar score at 10 minutes

    from 0-10 minutes

Study Arms (3)

Amniotomy first

ACTIVE COMPARATOR

Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.

Procedure: Amniotomy first

Oxytocin first

ACTIVE COMPARATOR

The starting dose will be the low dose rate equal or less than 4 m unit\\minute (4 drops\\minute doubled every 15 minutes up to 40 drops \\minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.

Procedure: Oxytocin firstDrug: Oxytocin

Amniotomy and oxytocin

ACTIVE COMPARATOR

Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.

Procedure: Amniotomy and oxytocinDrug: Oxytocin

Interventions

rupture of membranes to augment labor

Amniotomy first

Administration of oxytocin to augment labor

Oxytocin first

Rupture of membranes and administration of oxytocin to augment labor

Amniotomy and oxytocin
Amniotomy and oxytocinOxytocin first

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women in spontaneous labor
  • Women with intact membranes at the time of randomization
  • Single fetus
  • Vertex presentation
  • Cervical dilatation 3 cm or more
  • Gestational age 37 weeks or more proved by reliable dates or by early ultrasound scan in the first trimester
  • Slow progress in the active phase of labor ( cervical dilatation less than 1 cm \\hour)

You may not qualify if:

  • Women with a previous uterine scar
  • Severe preeclamptic toxemia
  • Suspected fetal macrosomia (greater than 4000 g)
  • Women with any congenital malformations
  • Women with Intra uterine fetal death
  • Diabetes mellitus with pregnancy
  • Antepartum hemorrhage
  • Women with other indications of caesarean section

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

AmniotomyOxytocin

Intervention Hierarchy (Ancestors)

Labor, InducedDelivery, ObstetricObstetric Surgical ProceduresSurgical Procedures, OperativePituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

October 5, 2014

First Posted

December 17, 2014

Study Start

April 1, 2014

Primary Completion

September 1, 2014

Study Completion

December 1, 2015

Last Updated

November 21, 2017

Record last verified: 2017-11